Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Christopher Pleyer, MD
Articles by Christopher Pleyer, MD
Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.